Janux Therapeutics, Inc. (JANX)

US — Healthcare Sector
Peers: INBX  MLYS  CLYM  ANEB  JBIO  IPSC  GLUE  EWTX  DAWN 

Automate Your Wheel Strategy on JANX

With Tiblio's Option Bot, you can configure your own wheel strategy including JANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol JANX
  • Rev/Share 0.1511
  • Book/Share 16.3852
  • PB 1.4657
  • Debt/Equity 0.0223
  • CurrentRatio 58.4698
  • ROIC -0.1097

 

  • MktCap 1421092428.0
  • FreeCF/Share -0.7531
  • PFCF -30.5388
  • PE -19.0879
  • Debt/Assets 0.0215
  • DivYield 0
  • ROE -0.0929

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation JANX Raymond James -- Outperform -- $65 July 11, 2025
Reiterated JANX BTIG Research -- Buy $82 $100 Dec. 3, 2024
Reiterated JANX H.C. Wainwright -- Buy $63 $70 Dec. 3, 2024
Initiation JANX Stifel -- Buy -- $70 Sept. 6, 2024

News

About Janux Therapeutics, Inc. (JANX)

  • IPO Date 2021-06-11
  • Website https://www.januxrx.com
  • Industry Biotechnology
  • CEO David Alan Campbell
  • Employees 91
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.